Emtron

Emtron Dosage/Direction for Use

ondansetron

Manufacturer:

Agio Pharma

Distributor:

AA Medical
Full Prescribing Info
Dosage/Direction for Use
Chemotherapy and radiotherapy: Adults: The emetogenic potential of cancer treatment varies according to the doses combinations of Chemotherapy and radiotherapy regimens used. The route administration and doses of Ondansetron should be flexible in the ranges of 8-32 mg a day and selected as shown below.
Emetogenic chemotherapy and radiotherapy: Ondansetron can be given either by rectal, oral (tablet or syrup), intravenous or intramuscular administration. For most patient receiving emetogenic chemotherapy and radiotherapy, ondansetron 8 mg should be administered as slow intravenous or intramuscular injection immediately before treatment, followed by 8 mg orally twelve hourly. To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with Ondansetron should be continued for up to 5 days after a course of treatment. Highly emetogenic chemotherapy: For patient highly receiving emetogenic chemotherapy, eg. high dose cisplatin, Ondansetron can be given by rectal, intravenous or intramuscular administration. Ondansetron has been shown to be equally effective in the following dose schedules over the first 24 hours of chemotherapy. A single dose 8 mg by slow intravenous or intramuscular injection immediately before chemotherapy. A dose of 8 mg by slow intramuscular injection immediately, before chemotherapy followed by two further intravenous or intramuscular doses of 8 mg two to four apart, or by a constant infusion of 1 mg/hour for up to 24 hours. A single dose of 32 mg diluted in 50-100 ml of saline or other compatible infusion fluid and infused over not less than 15 minutes immediately before chemotherapy. The selection of regimen should be determined by the severity of the emetogen challenge. The efficacy of Ondansetron in highly emetogenic chemotherapy may be enhanced by the addition of the single intravenous dose of dexamethasone sodium phosphate, 20 mg administered prior to chemotherapy. To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with Ondansetron should be continued for up to 5 days after a course of treatment.
Children: Ondansetron may be administered as a single intravenous dose of 5 mg/m2 immediately before chemotherapy, followed by 4 mg orally twelve hours later. 4 mg orally twice daily should be continued for up to 5 days after a course of treatment.
Elderly: Ondansetron is well tolerated by over 65 years and no alteration of dosage, dosing Frequency or route of administration are required.
Patients with Renal Impairment: No alteration of daily dosage or frequency of dosing, or route of administration are required.
Patients with Hepatic Impairment: Clearance of ondansetron is significantly reduced and serum half-life significantly. Prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a totally daily dose of 8 mg should not be exceed.
Postoperative nausea and vomiting (PONV): Adults: For the prevention of PONV Ondansetron can be administered orally or by intravenous injections or intramuscular injection. Ondansetron may be administered as a single dose of 4 mg given by intramuscular or slow intravenous injection is recommended.
Children (aged 2 years and over): For prevention of PONV in patients having surgery performed under general anaesthesia, Ondansetron may be administered injection at a dose of 0.1 mg/kg up to a maximum of 4 mg.
There is limited data on the use of Ondansetron in the prevention and treatment of PONV in children under 2 years of age.
Patients with Renal Impairment: No alteration of daily dosage or frequency of dosing, or route of administration are required.
Patients with Hepatic Impairment: Clearance of ondansetron is significantly reduced and serum half-life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceed.
Route of Administration: Emtron may be given intravenously.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in